Results 1 to 10 of about 123,788 (120)

Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?

Biology, 2020
Approximately 10% of the epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer (NSCLC) are uncommon EGFR mutations. Although the efficacy of second (2G) or third generation (3G) EGFR tyrosine kinase inhibitors (EGFR-TKIs) in the
Hyun Ae Jung, Sehhoon Park, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park   +6 more
doaj   +1 more source

Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study. [PDF]

PLoS ONE, 2015
Epidermal growth factor receptor (EGFR) mutations are the strongest response predictors to EGFR tyrosine kinase inhibitors (TKI) therapy, but knowledge of the EGFR mutation frequency on lung adenocarcinoma is still limited to retrospective studies.
Yuankai Shi, Junling Li, Shucai Zhang, Mengzhao Wang, Shujun Yang, Ning Li, Gang Wu, Wei Liu, Guoqing Liao, Kaican Cai, Liang'an Chen, Meizhen Zheng, Ping Yu, Xiuwen Wang, Yunpeng Liu, Qisen Guo, Ligong Nie, Jiwei Liu, Xiaohong Han   +18 more
doaj   +1 more source

Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity

npj Precision Oncology, 2021
Approximately 15–30% of patients with lung cancer harbor mutations in the EGFR gene. Major EGFR mutations (>90% of EGFR-mutated lung cancer) are highly sensitive to EGFR tyrosine kinase inhibitors (TKIs). Many uncommon EGFR mutations have been identified,
Takahiro Yoshizawa, Ken Uchibori, Mitsugu Araki, Shigeyuki Matsumoto, Biao Ma, Ryo Kanada, Yosuke Seto, Tomoko Oh-hara, Sumie Koike, Ryo Ariyasu, Satoru Kitazono, Hironori Ninomiya, Kengo Takeuchi, Noriko Yanagitani, Satoshi Takagi, Kazuma Kishi, Naoya Fujita, Yasushi Okuno, Makoto Nishio, Ryohei Katayama   +19 more
doaj   +1 more source

Detection and Significance of Cell-Free DNA Mutation in Pleural Effusion in Patients with Advanced NSCLC

Emergency Medicine International, 2022
Objective. To detect EGFR/KRAS genes in pleural effusion cell-free DNA in patients with advanced non-small-cell lung cancer (NSCLC) and to explore the clinical significance of EGFR/KRAS mutation status in pleural effusion. Methods.
Man Qiao, Dongsheng Li, Yuan He, Cen Zhang, Hang Chi, Xiaoqiu Li, QingMing Cui, ShaoYing Li, Ying Jiao, Yuan Wei   +9 more
doaj   +1 more source

Circulating plasma lncRNAs as novel markers of EGFR mutation status and monitors of epidermal growth factor receptor‐tyrosine kinase inhibitor therapy

Thoracic Cancer, 2020
Background Epidermal growth factor receptor (EGFR) gene mutations predict tumor response to EGFR tyrosine kinase inhibitors (EGFR‐TKIs) in non‐small cell lung cancer (NSCLC).
Panpan Lv, Shaoxing Yang, Wenjing Liu, Haifeng Qin, Xiuhua Tang, Fangfang Wu, Zeyuan Liu, Hongjun Gao, Xiaoqing Liu   +8 more
doaj   +1 more source

Evaluation of EGFR mutation status by radiographic characteristics of MRI in NSCLC patients with brain metastasis

Di-san junyi daxue xuebao, 2019
Objective To investigate the correlation between brain metastatic MRI features and EGFR mutation status in the patient with non-small cell lung cancer (NSCLC) and explore the value of radiographic characteristics of MRI for evaluation of EGFR mutation ...
HE Rong, ZHANG Zhimin, HE Xuan
doaj   +1 more source

Investigation on the Possibility of EGFR Mutation Testing on DNA Extracted from 
Fixation Liquid of Lung Cancer Biopsy

Chinese Journal of Lung Cancer, 2019
Background and objective Epidermal growth factor receptor (EGFR) mutation is the most common gene mutation in patients with non-small cell lung cancer (NSCLC).
Xuanzhi LIAO, Yingying GU, Juhong JIANG
doaj   +1 more source

S645C Point Mutation Suppresses Degradation of EGFR to Promote Progression of Glioblastoma

Frontiers in Oncology, 2022
BackgroundThe tightly controlled activity of EGFR is important for the homeostasis of self-renewal of human tissue. Mutations in the extracellular domain of EGFR are frequent and function as a novel mechanism for oncogenic EGFR activation in GBM, and ...
Wenda Huang, Ling Zou, Zhaonian Hao, Baofeng Wang, Feng Mao, Qiuhong Duan, Dongsheng Guo   +6 more
doaj   +1 more source

Clinical Features of EGFR Double Mutation in Non-small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2018
Background and objective The clinical features of patients with common single-mutation of epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) has been well characterized.
Mengyao WANG, Dunqiang REN, Caihong GUO, Xiaoqian DING, Hongmei WANG   +4 more
doaj   +1 more source

Population-based incidence rates and increased risk of EGFR mutated non-small cell lung cancer in Māori and Pacifica in New Zealand.

PLoS ONE, 2021
BackgroundNon-squamous non-small cell lung cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) mutation benefit from targeted treatments.
Phyu Sin Aye, Mark James McKeage, Sandar Tin Tin, Prashannata Khwaounjoo, J Mark Elwood   +4 more
doaj   +1 more source